Preclinical studies suggest that antiangiogenics can induce HRD through microenvironment hypoxia and downregulation of homologous recombination repair genes, thereby sensitizing tumour cells to PARP inhibitors.8 This evidence concerns the gene PARP1 and neoplasm.